Snap-8

Snap-8 (Acetyl Octapeptide-3) is a synthetic linear peptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2, developed by the Spanish cosmetic-ingredient company Lipotec (now part of Lubrizol/IFF) as a direct structural extension of Argireline (Acetyl Hexapeptide-8), also built on this site. Where Argireline's sequence covers six residues of the natural SNAP-25 protein's N-terminal region, Snap-8 extends this by two additional C-terminal residues (alanine and aspartic acid), intended to more completely replicate the natural SNAP-25 binding domain.

At Verified Peptides, we want to flag a naming detail directly: some secondary sources and even a chemical-database listing we reviewed during this research process mislabel Snap-8 as 'Acetyl Octapeptide-1,' which is a genuine naming inconsistency in circulation, though the CAS number (868844-74-0) and sequence data across the majority of vendor and technical sources consistently identify this specific 8-residue sequence as Acetyl Octapeptide-3/Snap-8.

Chemically, Snap-8 has molecular formula C41H70N16O16S, molecular weight approximately 1075.16 g/mol, CAS number 868844-74-0, UNII 8K14HJF88S. We independently cross-calculated this molecular weight atom-by-atom from the formula and confirmed it matches vendor-reported figures; we identified a real formula discrepancy in one database source (which listed C42H72N16O15S, a formula that does not match our independent atom-by-atom calculation from the known amino acid sequence) and are therefore not including a PubChem CID here, since we could not confirm which CID entry, if any, correctly represents this exact compound.

To arrive at our confirmed formula, we summed the constituent free amino acid formulas (glutamic acid x2, methionine, glutamine, arginine x2, alanine, aspartic acid), subtracted seven water molecules for the seven peptide-bond condensations joining the eight residues into a single chain, then applied the atom-count changes for N-terminal acetylation (net addition of C2H2O) and C-terminal amidation (net addition of one nitrogen and one hydrogen, net removal of one oxygen). This step-by-step derivation independently reproduced C41H70N16O16S and a molecular weight of approximately 1075.17 g/mol, matching the vendor-reported 1075.16 g/mol figure closely enough to treat as confirmatory.

At Verified Peptides, we found two real, peer-reviewed, PubMed-indexed clinical studies that include Snap-8, and we want to be direct about an important limitation shared by both: neither isolates Snap-8 as a standalone single-ingredient intervention. Avcil et al. (2020, Journal of Cosmetic Dermatology, PMID 31134751) tested a hyaluronic acid microneedle patch containing Snap-8 alongside an arginine/lysine polypeptide, palmitoyl tripeptide-5, adenosine, and seaweed extracts, in a 12-week clinical study reporting a 25.8% decrease in fine lines/wrinkles alongside improvements in hydration, density, and thickness — genuine clinical outcome data, but for a five-ingredient combination product, not Snap-8 alone. Shin et al. (2024, Annals of Dermatology, PMID 39082657) tested a different dissolving microneedle patch combining Snap-8 with a vitamin C derivative and sodium cyclic lysophosphatidic acid in a 24-subject, 28-day, split-face, placebo-controlled design, reporting improved wrinkle measurements, reduced transepidermal water loss, and improved elasticity versus placebo — again, real controlled clinical data, but for a three-ingredient combination, not an isolated Snap-8 monotherapy trial.

We want to be equally direct about a widely circulated claim we deliberately did NOT use as an independently verified citation: a manufacturer (Lipotec) in-house study reporting a 63.18% maximum wrinkle-depth reduction after 28 days of twice-daily 10% Snap-8 solution in 17 healthy female volunteers, using laser scanning microscopy on periocular skin silicone imprints, is repeated across a very large number of vendor and informational websites, sometimes phrased in ways that could be mistaken for independent peer-reviewed confirmation. We could not locate this specific study in any independently indexed, peer-reviewed journal — it appears to be Lipotec's own technical/marketing dossier data, a legitimate but manufacturer-sourced dataset, structurally similar to the manufacturer-versus-independent-evidence gap we have documented for other cosmetic peptides in this catalog, including Argireline and Leuphasyl. We are not including this specific figure as a research_papers citation, though we think it is honest to note that Snap-8's reputation as 'about 30% more effective than Argireline' in vendor marketing traces substantially back to this single, non-independently-published manufacturer dataset rather than to independently replicated peer-reviewed research. We want to name the general pattern this illustrates, since we expect to keep encountering it across cosmetic-ingredient research: a peptide can have a genuine, defensible research basis (SNAP-25 mimicry is real, published biochemistry, and Snap-8 does appear in real peer-reviewed clinical studies) while the SPECIFIC comparative-superiority number attached to it in commercial marketing traces to unpublished manufacturer data rather than independent replication. Both things can be true simultaneously — the ingredient itself is not fraudulent, but the specific competitive claim attached to it deserves separate, independent scrutiny rather than being accepted simply because the underlying compound is real.

No FDA, EMA, or other Western regulatory body evaluates Snap-8 as a drug, since it is regulated as a cosmetic ingredient. At Verified Peptides, we sell research-grade Snap-8 exclusively for laboratory research.

Snap-8 is one of several peptides in the Argireline/SNAP-25-mimic family developed by Lipotec, illustrating a common cosmetic-ingredient development pattern: once an initial short bioactive fragment (Argireline's 6 residues) shows commercial promise, manufacturers frequently develop extended or modified variants (Snap-8's 8 residues) intended to improve on the original, marketed with claims of superior potency that are often supported primarily by the manufacturer's own technical literature rather than by independently replicated academic research.

The two real peer-reviewed studies we identified for Snap-8 (Avcil 2020, PMID 31134751; Shin 2024, PMID 39082657) both used microneedle patch delivery systems rather than simple topical cream or serum application, reflecting a broader trend in cosmetic dermatology research toward microneedling-based delivery to improve penetration of peptide actives, including SNAP-25-mimicking peptides like Snap-8, past the skin's outer barrier layer.

The formula discrepancy we identified in this build (one database listing C42H72N16O15S versus our independently calculated C41H70N16O16S from the known amino acid sequence) is a useful illustration of why we cross-calculate molecular formulas from sequence data rather than accepting a single database entry, a practice that has also caught a real vendor data error for a different, unrelated compound in this catalog.

Lipotec's broader peptide portfolio also includes other extended or modified relatives of the original Argireline sequence beyond Snap-8, reflecting a general cosmetic-ingredient industry pattern of iterating on a single validated bioactive fragment to produce a family of related, separately trademarked and separately marketed ingredients, each requiring its own independent verification of evidence quality rather than assuming shared research support across the family.

At Verified Peptides, we require independent third-party HPLC purity testing and mass spectrometry identity confirmation for every batch of research-grade Snap-8 we offer, with a Certificate of Analysis (COA) available for each lot. As an 8-residue synthetic peptide with N-terminal acetylation and C-terminal amidation, both modifications should be confirmed as part of identity testing, not just the underlying amino acid sequence alone.

We source exclusively from manufacturers operating under Good Manufacturing Practice (GMP)-aligned quality systems, and every lot is independently verified rather than accepted solely on a supplier's internal documentation. Researchers should always request and review the specific COA for the lot they receive, confirming purity percentage and molecular identity before use in any experimental protocol.

Lyophilized Snap-8 is stable when stored at -20°C, protected from light and moisture. At Verified Peptides, we ship lyophilized peptide with appropriate cold-chain packaging to preserve stability in transit.

Once reconstituted, solution should be stored refrigerated at 2–8°C and used within the timeframe indicated on the product's documentation, avoiding repeated freeze-thaw cycles, which is a standard handling precaution across most of the short synthetic peptides in this catalog.